dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids 15 February 2024
First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024... Read more
First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024... Read more
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s... Read more
Copenhagen, Denmark, 13 February 2024 – Curasight A/S (“Curasight” or the “Company”... Read more
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces... Read more
CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or... Read more
Hørsholm, Denmark, 22 January 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more
Copenhagen, January 22, 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER:... Read more